Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Mayer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Gates Open Research|September 25, 2019
DataPackageR: Reproducible data preprocessing, standardization and sharing using R/Bioconductor for collaborative data analysisGreg Finak, Bryan Mayer, William Fulp, et al.
Journal of Virology|April 17, 2026
Clinical trial simulation of antiviral drugsJoshua T Schiffer, Daniel B Reeves, Bryan Mayer, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Plos One|August 9, 2019
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z Cohen, Allison L Butler, Katrina Millard, et al.
Nature Medicine|October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trialKathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Gates Open Research|September 25, 2019
DataPackageR: Reproducible data preprocessing, standardization and sharing using R/Bioconductor for collaborative data analysisGreg Finak, Bryan Mayer, William Fulp, et al.
Journal of Virology|April 17, 2026
Clinical trial simulation of antiviral drugsJoshua T Schiffer, Daniel B Reeves, Bryan Mayer, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Plos One|August 9, 2019
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z Cohen, Allison L Butler, Katrina Millard, et al.
Nature Medicine|October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trialKathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Pageof 1